pharma news today glp-1 obesity drugs The Disruptive Power of Weight Loss Is Being Felt Beyond health pharma news today obesity

[DOI] [PubMed] [Google Scholar] 138.Clemmensen C, Finan B, Mller TD, et al

Although limited direct evidence has evaluated use of GLP-1s with or without RDN-provided MNT, the SCALE [13], STEP 1 [14], SURMOUNT [15], and STEP 3 [169] trials each demonstrated substantial weight reduction by combining GLP-1s with regular counseling sessions by RDNs or other qualified healthcare professionals (such lifestyle support was also provided to the placebo group in each trial)

Patients whose BMI increased had worse outcomes than those with a BMI reduction of 0% to less than 5%

(2014a)

Robert Kushner: All of the above you just said

Reza Eshraghi et al., Effects of GlucagonLike Peptide1 Receptor Agonists on Alcohol Consumption: A Systematic Review and MetaAnalysis, The Lancet (Nov